May 7, 2025
Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists
Adovate Awarded $800,000 by Virginia Catalyst for Phase 2 Clinical Trial of ADO-5030 for the Treatment of C. difficile Infections. This is the second Virginia Catalyst award supporting Adovate’s therapeutic development. Charlottesville, VA – March 10, 2025 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing therapies targeting adenosine receptors, today announced